Novo Nordisk to acquire Cardior Pharmaceuticals
Novo Nordisk is set to acquire German miRNA blocker specialist Cardior Pharmaceuticals GmbH for up to €1.025bn including milestone payments.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2191 entries already.
Entries by Thomas Gabrielczyk
NDM Pharma provides POC for NMD670
Researchers at NDM Pharma A/S and Aarhus University have demonstrated that their oral CIC-1 blocker NMD670 restores crosstalk between neurons and muscles in Myasthenia gravis.
Roche opens €90m gene therapy development centre
Basel-headquartered Roche AG has inaugurated a brand new €90m gene therapy development centre in Penzberg near Munich.
AstraZeneca to take over Fusion Therapeutics Inc
British pharma giant AstraZeneca has announced to acquire radio-conjugate specialist Fusion Therapeutics Inc for US$2bn upfront.
Senisca Ltd raises £3.7m seed money
Exeter-based university spin-out Senisca Ltd has added £3.7m seed money to a £1.1m not dilutive funding to advance its pipeline of drugs targetting RNA splicing dysregulation.
A novel BPM system
The biotech and pharma branch is growing steadily. Many companies have full order books for the next few years and expect growth. This is the basis for new investments in assets and infrastructure. These growing structures often expose vulnerabilities and challenges for the business. Therefore, companies need to increase the stability and efficiency of their processes.
AstraZeneca to acquire Amolyt Pharma for up to US$1.05bn
French endocrine diseases specialist Amolyt Pharma SA has entered into a take-over agreement by AstraZeneca.
Relation Therapeutics Ltd bags US$35m in seed financing.
London-based virtual drug discovery specialist Relation Therapeutics Ltd has closed another US$35m seed financing round, bringing its total seed fundraise to US$60m.
Researcher find potential target for atherosclerosis
TREM2, a receptor on the surface of macrophages, reduces necrotic core formation in early atherosclerosis, a German-Austrian reseach team reports.
The EU Commission strikes again – New patent ban?
In times of the pandemic it was called to ban patents that are related to Covid-19 vaccines, medicaments, and diagnostics and the European Parliament was in favour of it. Now there is a call from the European Parliament to ban all patents on new genomics techniques (NTG) and plants. Quo vadis?